Thus, in HFrEF patients where obesity appears to be a major contributor to symptoms, prescribing GLP‐1 RAs should be preceded by a discussion between the patient, the caregiver, and the clinician about the absence of supporting evidence.38 This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.